Peptide Library / Detail

Deslorelin

GnRH Agonist PeptideResearch use only

Half-life

Sustained release over 6-12 months from implant formulation

Delivery

Subcutaneous implant (slow-release formulation)

Dosage

—

Research Use Only

All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.

Purchase

No purchase links available

Description

Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist peptide used primarily in veterinary medicine for reproductive control and hormonal manipulation. It works by initially stimulating and then suppressing the hypothalamic-pituitary-gonadal axis, leading to reversible suppression of reproductive function. The peptide is commonly administered as a slow-release subcutaneous implant for temporary contraception and management of hormone-dependent conditions in various animal species.

Usage

Typically administered as subcutaneous implants in doses ranging from 4.7 mg to 9.4 mg depending on species and body weight. In dogs, 4.7 mg implants are standard for males and females. In cats (queens), 9.4 mg implants are used. Duration of effect varies by species: approximately 6-12 months in dogs, with suppression beginning 4-6 weeks post-implantation. Implant location can affect efficacy, with interscapular placement commonly used.

Mechanism of Action

Deslorelin acts as a potent GnRH agonist that initially causes a surge in follicle-stimulating hormone (FSH) and luteinizing hormone (LH), followed by receptor desensitization and downregulation of the pituitary-gonadal axis. This results in decreased testosterone production in males and suppression of estrous cycles in females. The peptide influences androgen receptor expression and prostaglandin metabolism in reproductive tissues, leading to reversible suppression of spermatogenesis, testicular function, and ovarian activity (PMID: 41349370). In females, it can also be used at lower doses to induce ovulation before suppression occurs.

Benefits(7)

Reversible contraception in both male and female animals
Non-surgical alternative to permanent sterilization
Induction of ovulation in females when used in specific protocols
Management of hormone-dependent behavioral issues
Reduction of testosterone-related conditions in males
Treatment option for reproductive tract disorders
Predictable duration of action with slow-release formulations

Side Effects(8)

Initial hormonal surge before suppression (flare effect)
Temporary behavioral changes during downregulation phase
Local reactions at implant site including swelling or discomfort
Histomorphological changes in reproductive tissues (epididymis, testes)
Variable time to onset and recovery of fertility
Potential for incomplete suppression in some individuals
Changes in osteopontin expression in testicular tissue (PMID: 40795801)
Altered serum proteomic profiles during reproductive manipulation